# Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

*PRI Rank #14 · Topics and Trends in Most Cited Tuberculosis Research and Epidemiology Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/tuberculosis-research-and-epidemiology/2026/rank-14*

| Field | Value |
| --- | --- |
| Rank | #14 |
| 18m citations | 36 |
| Journal | The Lancet Infectious Diseases |
| Year | 2024 |
| DOI | 10.1016/s1473-3099(24)00223-8 |
| Corresponding authors | Müge Çevik |
| Institution | University of St Andrews, United Kingdom |

**Ranking page:** [Topics and Trends in Most Cited Tuberculosis Research and Epidemiology Papers, Class of 2026](https://pri.pepkio.com/top-papers/tuberculosis-research-and-epidemiology/2026)

**Paper link:** [10.1016/s1473-3099(24)00223-8](https://doi.org/10.1016/s1473-3099(24)00223-8)

## Topics

bedaquiline · pretomanid · moxifloxacin · pyrazinamide · Drug-susceptible tuberculosis · Drug-resistant tuberculosis · pulmonary tuberculosis · phase 2c trial · four-drug regimen · BPaMZ regimen · tuberculosis treatment shortening · Rifampicin-resistant tuberculosis · Multidrug-resistant tuberculosis · partially randomised design · treatment efficacy · safety profile · culture conversion · novel TB regimen

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Tuberculosis Research and Epidemiology Papers, Class of 2026. https://pri.pepkio.com/top-papers/tuberculosis-research-and-epidemiology/2026. Accessed 2026-07-24.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```